# Advances in basic and clinical research of flumatinib

## TL;DR

Flumatinib, a new Chinese-developed drug, shows better effectiveness than imatinib in treating chronic myeloid leukemia and other cancers.

## Contribution

Flumatinib demonstrates superior efficacy and safety compared to imatinib in treating CML and related diseases.

## Key findings

- Flumatinib inhibits CML cell lines more effectively than imatinib.
- Flumatinib shows better clinical outcomes than imatinib in treating CML.
- Flumatinib is effective against Ph chromosome-positive ALL and certain solid tumors.

## Abstract

慢性髓性白血病（CML）是一种起源于多能造血干细胞的恶性血液病。伊马替尼是第一代小分子酪氨酸激酶抑制剂（TKI），使CML的治疗取得了革命性进展。氟马替尼为我国自主研发的新型口服TKI药物，可作为CML治疗的优选方案。基础研究提示氟马替尼对CML细胞株抑制作用强于伊马替尼，临床试验及真实世界中氟马替尼对CML疗效均优于伊马替尼，且氟马替尼对Ph染色体阳性急性淋巴细胞白血病、ABL特定突变CML及部分实体瘤有疗效。不良反应可控，安全可耐受。